On August 5, DaVita HealthCare Partners fell 5.94% in pre-market trading, trading at $218.0/share, with turnover of $23,200.

The decline follows the company's Q2 earnings release, where adjusted EPS of $4.02 beat the consensus estimate of $3.88 by 3.61%, representing a 36.27% year-over-year increase from $2.95. Revenue of $3.554 billion also exceeded the $3.496 billion estimate. Despite the strong quarter, the company maintained its full-year adjusted EPS guidance at $14.10-$15.20, with a midpoint of $14.65 falling below the market consensus of $14.88. Given consecutive significant beats in Q1 and Q2, investors had widely anticipated a guidance raise, and the unchanged outlook is being interpreted as an implicit signal of decelerating earnings growth in the second half.

Adding to sentiment pressure, SEC filings revealed that Berkshire Hathaway recently sold 182,980 shares of DaVita at an average price of $199.55, though it still retains approximately 28.7 million shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)